JAZZ Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$288.00median target· current $245.57 (+17.3%)20 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio16.69Forward 18.94
EPS (TTM)$14.603.2% YoY
Profit margin20.4%HEALTHCARE
Market cap$15.82BLarge cap
Valuation
- Forward P/E
- 18.94
- PEG ratio
- 0.96
- P/B
- 3.39
- P/S (TTM)
- 3.44
- EV/EBITDA
- 11.43
Profitability & growth
- ROE (TTM)
- 22.1%
- Operating margin
- 26.9%
- Revenue growth YoY
- 15.5%
- Dividend yield
- —
- Beta
- 0.36
Last earnings
Aug 3, 2026 · Estimate $5.06 · Reported $4.89
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Jazz Pharmaceuticals PLC
Company profileJazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Dublin, Ireland.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- WATERLOO EXCHANGE, DUBLIN, IRELAND
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$15.82B
Shares outstanding$64.9M
52W high$266.38
52W low$123.88
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent